Bolt Biotherapeutics Presents Preclinical Results From Next-Generation Boltbody ISACs Targeting CEACAM5 And PD-L1 At AACR Annual Meeting

-1.00%

Bolt Biotherapeutics, Inc.

BOLT

0.00

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs

PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Have Insiders Sold Immunovant Shares Recently?

A Look at Alvotech (NasdaqGM:ALVO) Valuation Following FDA Setback and Revenue Guidance Cut

Bristol Myers Squibb Announces Virtual Investor Event to Highlight Hematology Programs

Belite Bio Assigns Columbia University License to Swiss Subsidiary

Novo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial

Cidara Therapeutics Reaches Target Enrollment Of Phase 3 ANCHOR Trial Evaluating CD388

Verrica Pharmaceuticals Announces $4.24M Private Placement With Common Stock, Pre-Funded Warrants And Series C Warrants

Purple Biotech's TyrNovo Has Been Granted European Patent Number EP3750530 Titled "COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER"